Amgen vs Pfizer
AMGN and PFE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMGN and PFE compare
Amgen is the larger company, worth 1.5 times as much as Pfizer ($252B against $171B).
On earnings, Amgen is cheaper: it trades at 28.9× trailing earnings, against 39.4× for Pfizer.
Amgen grew revenue faster over the last twelve months (9.1% versus −0.21% for Pfizer).
Amgen keeps more of each dollar of sales as profit, with a net margin of 23.0% compared with 6.8% at Pfizer.
Both pay dividends: Amgen yields 2.1% and Pfizer 5.7%.
Amgen scores higher on the StockData Score (17 against 11 for Pfizer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMGN | PFE |
|---|---|---|
| Size and price | ||
| Market cap | $252B | $171B |
| Share price | $466.01 | $29.95 |
| Change, 1 year | 59.7% | 22.2% |
| Change, 5 years | 118% | −38.4% |
| Beta (5Y) | 0.42 | 0.44 |
| Employees | 32K | 75K |
| StockData Score | ||
| Total score | 17 (better) | 11 |
| Valuation score | 0 | 1 (better) |
| Growth score | 5 (better) | 2 |
| Performance score | 6 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 28.9× (better) | 39.4× |
| P/S | 6.6× | 2.7× (better) |
| P/B | 21.6× | 2.0× (better) |
| EV/EBITDA | 20.9× | 16.7× (better) |
| P/FCF | 24.8× | 15.5× (better) |
| PEG | 5.24 | – |
| FCF yield | 4.0% | 6.4% (better) |
| Fair value | $334.49 | $19.52 |
| Margin of safety | −39.3% (better) | −53.4% |
| Growth | ||
| Revenue growth (TTM) | 9.1% (better) | −0.21% |
| Revenue growth, 5Y average | 7.6% | 8.5% (better) |
| Net income growth (TTM) | 32.1% (better) | −59.7% |
| EPS growth (TTM) | 31.6% (better) | −59.6% |
| EPS growth, 5Y average | 2.9% (better) | −3.6% |
| Profitability | ||
| Gross margin | 69.5% | 73.2% (better) |
| Operating margin | 30.0% | – |
| Net margin | 23.0% (better) | 6.8% |
| FCF margin | 26.7% (better) | 17.2% |
| Return on equity | 91.5% (better) | 5.0% |
| Return on invested capital | 17.6% | – |
| Financial health | ||
| Debt / equity | 4.90 | 0.74 (better) |
| Net debt / EBITDA | 3.07 (better) | 4.07 |
| Interest coverage | 4.3× | – |
| Current ratio | 1.37 (better) | 1.27 |
| Altman Z-score | 2.39 (better) | 2.03 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | 5.7% (better) |
| Payout ratio | 60.4% | – |
| Years of dividend growth | 9 | 15 (better) |
| Dividend growth, 5Y average | 8.0% (better) | 2.4% |
| Shareholder yield | 2.1% | 5.7% (better) |
| Ownership | ||
| Held by institutions | 82.7% | 67.2% |
| Held by insiders | 0.21% | 0.03% |
| Insider net buying, 12 months | −$29.3M | $2.8M (better) |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 2.6% | 2.6% |
Go deeper
- AMGN stock overview
- AMGN income statement
- AMGN valuation and score
- PFE stock overview
- PFE income statement
- PFE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.